Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pain drug could cut opioid use after tummy tucks

NCT ID NCT07102459

Symptom relief Sponsor: Latigo Biotherapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called LTG-001 for managing pain after a tummy tuck (abdominoplasty). 343 adults took either a high or low dose of LTG-001, a standard painkiller combination, or a placebo. Researchers measured pain relief over 48 hours and tracked how much extra opioid pain medication was needed. The goal was to see if LTG-001 works and is safe for short-term post-surgical pain.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LTG-001 (an experimental painkiller)
What this could lead to
If it works, this could provide a new option for managing short-term pain after surgery, possibly reducing the need for opioid painkillers.
What could go wrong
This is an early Phase 2 trial, so results may not confirm effectiveness or safety. The drug is only tested for 48 hours after one type of surgery, so it may not work for other pain types or longer periods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

343 people

The number who actually took part.

Started

Jul 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject is male or female aged 18 to 65 years * Scheduled to undergo an elective "partial" abdominoplasty under general anesthesia * Has a body BMI 18.0 to 35 kg/m2 * Has signed informed consent and will comply with the requirements and restrictions of the study * Meet lifestyle, medication, or other study restrictions * Subject must agree to study required use of birth control * Post-surgical (abdominoplasty) pain must meet the study threshold Exclusion Criteria: * Inability to take oral medications * Prior abdominoplasty or a prior intra-abdominal and/or pelvic surgery (including hysterectomy and Cesarean section) that resulted in any complications * History of impaired hepatic function or heart disease. * Abnormal liver laboratories or other lab abnormality indicative of serious medical condition * Sensory abnormality that would confound post-surgery pain assessments * Chronic use of NSAIDs, benzodiazepines, opioid use within the last year, use of medications that prolong QTc intervals, or other dietary and medication restrictions * A subject with sleep apnea and/or on a home continuous positive airway pressure machine. * Positive drug screen.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Acute Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute pain Postoperative pain control

Contacts and locations

Locations

  • Arizona Research Center

    Phoenix, Arizona, 85053, United States

  • CenExel ACMR

    Atlanta, Georgia, 30331, United States

  • Endeavor Clinical Research

    San Antonio, Texas, 78240, United States

  • HD Research LLC

    Houston, Texas, 77043, United States

  • JBR Clinical Research (CenExel)

    Salt Lake City, Utah, 84107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.